Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 6/20 | 0.58 |
| ▸ | MMP1 | P03956 | 2/20 | 0.58 |
| ▸ | NMUR2 | Q9GZQ4 | 6/20 | 0.55 |
| ▸ | NMUR1 | Q9HB89 | 6/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599754 | 1.00 | MMP3 (0.58) | MMP3MMP1NMUR2NMUR1OPRM1 | |
| SCHEMBL14599760 | 0.88 | OPRM1 (0.51) | MMP3MMP1NMUR2NMUR1OPRM1 | |
| SCHEMBL5555575 | 0.88 | OPRM1 (0.51) | MMP3MMP1NMUR2NMUR1OPRM1 | |
| SCHEMBL14599758 | 0.85 | MMP3 (0.53) | MMP3MMP1NMUR2NMUR1OPRM1 | |
| SCHEMBL5556497 | 0.82 | MMP3 (0.57) | MMP3MMP1NMUR2NMUR1OPRM1 | |
| SCHEMBL30629127 | 0.82 | NMUR2 (0.63) | NMUR2NMUR1OPRM1OPRK1OPRD1 | |
| SCHEMBL5551661 | 0.81 | MMP3 (0.52) | MMP3MMP1NMUR2NMUR1OPRM1 | |
| SCHEMBL6510374 | 0.80 | MMP3 (0.61) | MMP3MMP1NMUR2NMUR1OPRM1 | |
| SCHEMBL29366560 | 0.80 | NMUR2 (0.59) | NMUR2NMUR1OPRM1OPRK1OPRD1 | |
| SCHEMBL30678863 | 0.80 | NMUR2 (0.56) | MMP3MMP1NMUR2NMUR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | CA14, CA13, CA1 | MMP3 540/4885MMP1 179/4885NMUR2 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.